Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis / Segurança na mudança direta de natalizumabe para fingolimode em um grupo de pacientes com esclerose múltipla e positivos para JCV

ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.

RESUMO Objetivo Avaliar a segurança na mudança entre natalizumabe e fingolimode sem período de washout. Métodos Dados prospectivos de 25 pacientes positivos para vírus JC que tiveram sua medicação modificada foram coletados e analisados. Resultados Após uma mediana de nove meses da troca de medicação, não havia aspectos de segurança a relatar. Os pacientes estavam com bom controle da doença e não foram relatados eventos adversos. Conclusão Washout pode não ser necessário na prática diária para a mudança entre natalizumabe e fingolimode. No entanto, expertise no manejo de esclerose múltipla é essencial para esta troca entre medicações.

Tratamiento de la esclerosis múltipple: la era del natalizumab / Treatment of Multiple Sclerosis: the era of Natalizumab

La esclerosis múltiple es una enfermedad inflamatoria crónica y autoinmune del sistema nervioso central. Produce un variado abanico de síntomas que suelen llevar a la incapacidad del paciente que la padece. Para su tratamiento se ha empleado una amplia gama de drogas, todas destinadas a contrarrestar la respuesta inflamatoria. Entre ellas se destacan los corticoides, acetato de glatiramer, interferón beta, entre otras. Ninguna de ellas trata la causa primaria de la enfermedad pero pueden aminorar su progresión y retrasar la aparición de nuevos síntomas. Sin embargo, no son capaces de lograr el control de la enfermedad sin que sus efectos adversos o sus pautas y formas de administración se interpongan en la terpéutica. La introducción del natalizumab en el tratmiento de la esclerosis múltiple constituye un avance sin precedentes. Esta droga controla el progreso de la enfermedad como ninguna de sus antecesoras con una muy baja frecuencia de administración y una gran aceptación del tratamiento por parte de los pacientes. Sin embargo, el riesgo de aparición de leucoencefalopatía multifocal progresiva durante el tratamiento con natalizumab hace que su terapéutica requiera un enfoque multidisciplinario de profesionales de la salud

Multple Sclerosis is a chronic, inflammatory and autoimmune disease of the central nervous system. It causes a wide range of symptoms which may lead to the impairment of the patient that suffers from it. Numerous drugs have been used for its treatment to counteract the inflammatory response. Among these drugs are corticosteriods, glatiramer acetate and Interferon beta. Although none of them treat the primary cause of the disease, they may slow down its progression and delay the appearance of new symptoms. In addition, they are not capable of achieving the control of the disease without their adverse effects, guidelines, or ways of administration interposing in the therapeutic treatment. The introduction of natalizumab in the treatment of multiple sclerosis is an unprecedented advance. This drug controls the progression of the disease in a way which none of the former drugs has achieved, with a very low frequency of administration and a high treatment acceptance by the patients. However, the risk of developing progressive multifocal leukoencephalopathy during treatmente with natalizumab makes its therapeutic treatment require a multidisciplinary approach on the part of healthcare professionals

Head tremor and progressive multifocal leukoencephalopathy in AIDS patients: report of two cases

A leucoencefalopatia multifocal progressiva (LMP) é causada pela replicação do vírus JC em oligodendrócitos de pacientes imunocomprometidos. As manifestações mais comuns incluem déficits motores e sensitivos, alterações da marcha, da fala e da linguagem, cefaléia e distúrbios visuais e cognitivos. Embora a presença de distúrbios do movimento não seja tão freqüente na LMP, bradicinesia, rigidez, abalos mioclônicos e ataxia mioclônica já foram descritos. Nós relatamos dois casos de LMP associados com tremor cefálico.

Detection of JC virus infection in progressive multifocal leukoencephalopathy: the first documented case in Thailand.

Progressive Multifocal Leukoencephalopathy (PML) is a demyelinating brain disease caused by human polyoma JC virus (JCV). This disease is an important cause of morbidity and mortality in AIDS patients. Definite diagnosis currently requires a brain biopsy. PCR for JCV of CSF, an emerging diagnostic tool, has a high specificity for the diagnosis of PML in patients with characteristics on clinical and neuroradiological findings. The authors report a 36-year-old woman who presented with prolonged fever, progressive weakness, and slow speech for 2 months. Clinical features and MRI findings were compatible with PML. Qualitative PCR for JCV of CSF showed a positive result. This report emphasizes the yield of PCR, the CSF for JCV in a diagnosis of PML, which may reduce the need for a brain biopsy in such cases.

Leucoencefalopatia multifocal progressiva como manifestação inicial da síndrome da imunodeficiência adquirida / Progressive multifocal leukoencephalopathy as initial manifestation of acquired immunodeficiency

This is a report of a man with acquired immunodeficiency syndrome (AIDS) who presented acutely ill with severe progressive multifocal leukoencephalopathy (PML) as the first manifestation of AIDS. PML was diagnosed in the brain after gross and microscopical examination as well as by immunohistochemistry with an antibody against JC virus.

Relata-se caso de homem portador da Síndrome da Imunodeficiência Adquirida que apresentou quadro agudo e grave de Leucoencefalopatia Multifocal Progressiva (LMP) como primeira manifestação da Síndrome. A LMP foi caracterizada macro e microscopicamente e através de estudo imuno-histoquímico utilizando o anticorpo antivírus JC.

Co-infección encefálica por papovavirus (virus JC) y varicela Zoster en un paciente con SIDA / Encephalic co-infection by Papovavirus (JC Virus) and Varicella Zoster in an AIDS patient

Se presenta el caso clínico de una paciente infectada por el virus VIH, en etapa Sida, que desarrolló una co-infección por Popovavirus (Virus JC) y Varicella Zoster (V-Z) a nivel encefálico. Las manifestaciones clínicas e imagenológicas de ambos oportunistas son similares y a veces indistinguibles, tal como sucedió en esta paciente. La realización de la técnica denominada reacción en cadena de la polimerasa (PCR) aplicada al LCR; permitió establecer el diagnóstico. Se resalta la posibilidad de que coexistan estos dos oportunistas a nivel encefálico, posibilidad no reportada, en la literatura revisada, y la necesidad, dadas las similitudes existentes de discriminar ambas entidades. La detección del V-Z abre posibilidades terapéuticas mejorando el pronóstico de la intercurrencia infecciosa